ClinicalTrials.gg
RecruitingNCT07833930Updated Sep 22, 2026

Incidence and Clinical Features of Breakthrough Pain After Brachial Plexus Block in Diabetic Patients

An observational study in Postoperative Pain, sponsored by Second Hospital of Shanxi Medical University. Recruiting at 1 site in China. Open to participants aged 18 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-22.

Sponsored by Second Hospital of Shanxi Medical University · Observational

How we know

From the registry’s dates

  • Started Sep 2025; still recruiting 1 year 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Cross-sectional
Enrollment
216
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 249 studies in Pain, Postoperative with a site in China — 79 open to participants now, 81 under way, 3 of them phase 3. Pain, Postoperative · China.

Planned enrollment
27th of 43
216 · median 350
Started
2025
with 28 others
Observational
43 of 249
14 open now
Primary completion
2026-09
later than 40 of 80 live
Registered
246th of 249
by date

Among the 249 studies in Pain, Postoperative with a site in China, this one is the 27th largest by planned enrollment of the 43 observational ones that give a count, is one of 29 that started in 2025, is one of 43 observational ones, reaches primary completion later than 40 of the 80 other live ones, and was the 246th registered.

Pain, Postoperative

5,680 studies on the registry are indexed under Pain, Postoperative; 1,243 are open to participants now.

Browse Pain, Postoperative studies →

Open to participants now

79 of the 249 studies in Pain, Postoperative with a site in China are open now. Recruiting first, the newest first:

74 more — sign in →

All 79 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 678 Pain, Postoperative studies recruiting now, 239 (35%) set no upper age limit and 329 (49%) stop at 75 or younger; 74 take children under 18; 129 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 249 studies in Pain, Postoperative with a site in China, or all of them as a file.
02

Study summary

This observational study aims to determine the incidence and clinical characteristics of rebound-breakthrough pain after ultrasound-guided brachial plexus block in adult patients with type 2 diabetes mellitus. Adult patients undergoing elective upper-extremity surgery are divided into a type 2 diabetes group and a non-diabetic control group. Baseline clinical data and pain-related outcomes are collected after nerve block. This work may provide evidence for optimizing perioperative pain management for diabetic patients receiving brachial plexus block.

Read the detailed description

Background: Diabetes mellitus is a highly prevalent chronic disease worldwide. Diabetic peripheral neuropathy is one of its common complications, which may alter peripheral nerve function and pain perception. Brachial plexus block is widely used for upper-limb surgery. Rebound-breakthrough pain is a clinically important adverse event after peripheral nerve block, which worsens postoperative recovery and increases opioid consumption. The incidence and clinical features of this pain among patients with type 2 diabetes remain unclear.

This observational study enrolls adult patients undergoing elective upper-extremity surgery with ultrasound-guided brachial plexus block. Participants are separated into two groups: patients with type 2 diabetes mellitus and patients without diabetes. All patients receive routine clinical anesthesia with 0.375% ropivacaine for brachial plexus block without any experimental intervention. Pre-operative baseline information includes demographic data, glycosylated hemoglobin, diabetic history, and sensory threshold measurement. Post-block data including pain scores, onset and recovery time of sensory-motor block, patient-controlled analgesia usage and additional analgesic consumption are recorded.

The primary objective is to calculate the incidence of postoperative breakthrough-rebound pain. Secondary objectives cover pain severity, onset and duration of breakthrough pain, and perioperative analgesic consumption. Collected data will be summarized and analyzed to describe clinical characteristics associated with breakthrough pain.

03

Conditions studied

  • Postoperative Pain

Keywords

  • Brachial plexus block
  • Rebound pain
  • Type 2 diabetes mellitus
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Adult patients receiving ultrasound-guided brachial plexus block for elective upper-extremity surgery. Subjects are divided into two cohorts: patients with type 2 diabetes mellitus and non-diabetic patients. Routine clinical anesthesia management is adopted without experimental interventions.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged 18 years or older
  • Undergoing elective upper-extremity surgery
  • Planned for ultrasound-guided brachial plexus block with 0.375% ropivacaine
  • Able to cooperate with pain assessment and follow-up within 48 hours after block
  • Written obtained

Exclusion criteria

Exclusion Criteria:

  • Allergy or to amide-type local anesthetics
  • Pre-existing peripheral neuropathy of the affected upper limb
  • Chronic regular use of opioids before surgery
  • Coagulopathy or infection at the block puncture site
  • Cognitive dysfunction unable to complete NRS pain evaluation
  • Pregnancy or lactation
  • Incomplete clinical data expected during follow-up
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Observational model
Cohort
Time perspective
Cross-sectional
Enrollment
216 participants (estimated)
Patient registry
No

Groups and cohorts

  • Patients with type 2 diabetes mellitus

    Adult patients diagnosed with type 2 diabetes mellitus undergoing elective upper-extremity surgery with ultrasound-guided brachial plexus block. All subjects receive routine clinical anesthesia with 0.375% ropivacaine without experimental intervention.

  • Patients without diabetes mellitus

    Adult non-diabetic patients undergoing elective upper-extremity surgery with ultrasound-guided brachial plexus block. All subjects receive routine clinical anesthesia with 0.375% ropivacaine without experimental intervention.

06

What researchers measure

Primary outcomes

  1. Incidence of postoperative rebound-breakthrough pain

    Proportion of participants developing rebound-breakthrough pain within 48 hours after brachial plexus block.Rebound-breakthrough pain after peripheral nerve block is characterized by sudden severe pain (NRS ≥ 7) occurring within 24 hours after block resolution. It is typically burning in nature, may occur at rest or during movement, lasts more than 2 hours, and most frequently develops 12-24 hours postoperatively.

    Time frame: Within 48 hours after brachial plexus block

Secondary outcomes

  1. Within 48 hours after brachial plexus block

    Peak numerical rating scale (NRS, 0-10) score during each rebound-breakthrough pain episode. Higher score indicates more severe pain.

    Time frame: Within 48 hours after block

  2. Onset time of first rebound-breakthrough pain

    Time interval from completion of brachial plexus block to the first occurrence of rebound-breakthrough pain.

    Time frame: Within 48 hours after block

  3. Frequency of rebound-breakthrough pain episodes

    Total number of rebound-breakthrough pain episodes within 48 hours after brachial plexus block.

    Time frame: Within 48 hours after block

  4. Duration of each rebound-breakthrough pain episode

    Duration of each rebound-breakthrough pain episode that occurs within 48 hours after brachial plexus block.

    Time frame: Within 48 hours after block

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Sep 2025 (actual). Primary completion is estimated for Sep 2026, 12 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 12, 2026
First posted
Sep 22, 2026
StartActual
Sep 20, 2025
Primary completionEst.
Sep 20, 2026
CompletionEst.
Sep 20, 2026
Last update
Sep 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 22, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07833930
Lead sponsor
Second Hospital of Shanxi Medical University
Responsible party
Zheng Guo (Professor, Second Hospital of Shanxi Medical University) — Principal investigator
First posted
Sep 22, 2026
Start date
Sep 20, 2025
Primary completion
Sep 20, 2026 (estimated)
Completion
Sep 20, 2026 (estimated)
Last update
Sep 22, 2026

Study contacts

Wen bo Wang
Contact
1525565253@qq.com
+8618636532676
Li li Wang
study director · Second Hospital of Shanxi Medical University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion